Skip to main navigation Skip to search Skip to main content

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

  • Peter M. Voorhees
  • , Douglas W. Sborov
  • , Jacob Laubach
  • , Jonathan L. Kaufman
  • , Brandi Reeves
  • , Cesar Rodriguez
  • , Ajai Chari
  • , Rebecca Silbermann
  • , Luciano J. Costa
  • , Larry D. Anderson
  • , Nitya Nathwani
  • , Nina Shah
  • , Naresh Bumma
  • , Yvonne A. Efebera
  • , Sarah A. Holstein
  • , Caitlin Costello
  • , Andrzej Jakubowiak
  • , Tanya M. Wildes
  • , Robert Z. Orlowski
  • , Kenneth H. Shain
    • Andrew J. Cowan, Shira Dinner, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Saad Z. Usmani, Paul G. Richardson

Research output: Contribution to journal › Article › peer-review

151 Scopus citations

Fingerprint

Dive into the research topics of 'Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Immunology and Microbiology